Lexicon Announces Trial Results of LX4211 Combination Therapy

The study showed that single doses of LX4211 in combination with sitagliptin produced lower blood glucose levels after meals (postprandial) as compared to treatment with sitagliptin alone.

U.S. biopharmaceutical company Lexicon Pharmaceuticals has announced the top-line results from the first clinical study evaluating the combined effects of LX4211, a sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin (Januvia).

The study involved 18 type 2 diabetic patients, who received single doses of either LX4211 (400mg), sitagliptin (100mg) or LX4211 plus sitagliptin on days one, eight, or 15. The study assessed pharmacodynamic parameters, including postprandial glucose, insulin, total and active glucagon-like peptide-1, PYY, and urinary glucose excretion.

The study showed that single doses of LX4211 in combination with sitagliptin produced lower blood glucose levels after meals (postprandial) as compared